Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bistrum
- Development stage
- Unknown
- Lead developer
- Goldline Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bistrum is a marketed immunity-boosting product developed by Goldline Pharmaceuticals, an Indian specialty pharmaceutical company. It is positioned within the company's specialty care portfolio, which is specifically dedicated to cancer patients and survivors. Bistrum is designed to provide general immune support and enhance the body's natural defenses, serving as a supportive wellness product for individuals undergoing or recovering from intensive medical treatments. As a product of Goldline's wellness and specialty divisions, it is typically administered orally to maintain health and vitality.
- Brand names
- Bistrum
Beyond the preview
Go deeper on Bistrum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bistrum.